[{"id":"2d611a75-574e-482e-91b3-3bf96d4e7ace","acronym":"CATCHAML","url":"https://clinicaltrials.gov/study/NCT04318678","created_at":"2021-01-18T20:55:40.221Z","updated_at":"2025-02-25T12:27:32.189Z","phase":"Phase 1","brief_title":"CD123-Directed Autologous T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)","source_id_and_acronym":"NCT04318678 - CATCHAML","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" CD123 • IL3RA","pipe":"","alterations":" ","tags":["CD123 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cyclophosphamide • fludarabine IV • mesna • CD123-CAR T cell therapy • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 07/29/2020","start_date":" 07/29/2020","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2025-02-24"},{"id":"30691860-7f81-43a1-b334-a75b53b70fce","acronym":"","url":"https://clinicaltrials.gov/study/NCT04959175","created_at":"2021-07-13T12:53:21.217Z","updated_at":"2025-02-25T13:40:32.157Z","phase":"Phase 1/2","brief_title":"Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies","source_id_and_acronym":"NCT04959175","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • IGH","pipe":"","alterations":" ","tags":["EGFR • IGH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • sirolimus • fludarabine IV • mesna • Neupogen (filgrastim) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 320","initiation":"Initiation: 09/23/2021","start_date":" 09/23/2021","primary_txt":" Primary completion: 04/27/2027","primary_completion_date":" 04/27/2027","study_txt":" Completion: 04/30/2027","study_completion_date":" 04/30/2027","last_update_posted":"2025-02-21"},{"id":"ff4e0c3b-845b-4c81-ada0-12dd4b76209c","acronym":"","url":"https://clinicaltrials.gov/study/NCT06777979","created_at":"2025-02-25T13:57:28.881Z","updated_at":"2025-02-25T13:57:28.881Z","phase":"Phase 1","brief_title":"CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy for Pediatric Patients With Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT06777979","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" CD22","pipe":"","alterations":" ","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • mesna"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 05/01/2025","start_date":" 05/01/2025","primary_txt":" Primary completion: 01/01/2030","primary_completion_date":" 01/01/2030","study_txt":" Completion: 01/01/2031","study_completion_date":" 01/01/2031","last_update_posted":"2025-02-20"},{"id":"110cd83b-a31c-4b26-8b05-9ad93be67a86","acronym":"","url":"https://clinicaltrials.gov/study/NCT04530565","created_at":"2021-01-18T21:41:29.599Z","updated_at":"2025-02-25T14:07:51.985Z","phase":"Phase 3","brief_title":"Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults","source_id_and_acronym":"NCT04530565","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ABL1 • BCR","pipe":" | ","alterations":" ABL1 T315I","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ABL1 T315I"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • cytarabine • Iclusig (ponatinib) • doxorubicin hydrochloride • cyclophosphamide • Blincyto (blinatumomab) • methotrexate • vincristine • prednisone • dexamethasone • mesna • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous • dexamethasone injection"],"overall_status":"Recruiting","enrollment":" Enrollment 348","initiation":"Initiation: 01/25/2021","start_date":" 01/25/2021","primary_txt":" Primary completion: 07/01/2028","primary_completion_date":" 07/01/2028","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2025-02-19"},{"id":"99c4032a-3714-4351-a6af-2208fcba233e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04684368","created_at":"2021-01-19T20:47:18.675Z","updated_at":"2025-02-25T15:11:50.245Z","phase":"Phase 2","brief_title":"A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT","source_id_and_acronym":"NCT04684368","lead_sponsor":"Children's Oncology Group","biomarkers":" NF1","pipe":" | ","alterations":" AFP elevation","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AFP elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • cyclophosphamide • ifosfamide • etoposide IV • mesna • thiotepa • Neulasta (pegfilgrastim) • Fulphila (pegfilgrastim-jmdb) • Neupogen (filgrastim) • Udenyca (pegfilgrastim-cbqv) • Ziextenzo (pegfilgrastim-bmez) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 160","initiation":"Initiation: 07/13/2021","start_date":" 07/13/2021","primary_txt":" Primary completion: 12/21/2029","primary_completion_date":" 12/21/2029","study_txt":" Completion: 12/21/2029","study_completion_date":" 12/21/2029","last_update_posted":"2025-02-13"},{"id":"a3330799-3a3c-4c3b-bada-534a183f734f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05382338","created_at":"2022-05-19T11:56:15.604Z","updated_at":"2025-02-25T15:12:50.886Z","phase":"Phase 3","brief_title":"A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss","source_id_and_acronym":"NCT05382338","lead_sponsor":"Children's Oncology Group","biomarkers":" MYCN • GLI2","pipe":" | ","alterations":" TP53 wild-type","tags":["MYCN • GLI2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • cyclophosphamide • vincristine • lomustine • mesna"],"overall_status":"Suspended","enrollment":" Enrollment 225","initiation":"Initiation: 02/20/2023","start_date":" 02/20/2023","primary_txt":" Primary completion: 12/20/2027","primary_completion_date":" 12/20/2027","study_txt":" Completion: 12/20/2027","study_completion_date":" 12/20/2027","last_update_posted":"2025-02-13"},{"id":"2aac339a-fbd4-48aa-9c04-5e7a6adc7234","acronym":"NCI-MATCH","url":"https://clinicaltrials.gov/study/NCT02465060","created_at":"2021-01-17T17:15:30.769Z","updated_at":"2025-02-25T16:36:36.993Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","source_id_and_acronym":"NCT02465060 - NCI-MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["MSI • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bendamustine • bicalutamide • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • Fakzynja (defactinib) • GSK2636771 • Zirabev (bevacizumab-bvzr) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Paletan (pertuzumab biosimilar) • Provenge (sipuleucel-T) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Pertuvia (pertuzumab biosimilar) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6452","initiation":"Initiation: 08/17/2015","start_date":" 08/17/2015","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"fd746a04-cf2a-4fe6-8ac1-71be01980b12","acronym":"","url":"https://clinicaltrials.gov/study/NCT03016806","created_at":"2021-01-18T14:50:46.648Z","updated_at":"2025-02-25T14:14:55.178Z","phase":"Phase 1","brief_title":"Umbilical Cord Blood Transplantation From Unrelated Donors","source_id_and_acronym":"NCT03016806","lead_sponsor":"University of Rochester","biomarkers":" FLT3 • KMT2A","pipe":" | ","alterations":" MLL rearrangement • MLL rearrangement","tags":["FLT3 • KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • melphalan • fludarabine IV • mesna • busulfan • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 06/01/2015","start_date":" 06/01/2015","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2024-08-19"},{"id":"baf13e92-2865-4426-b17d-b77cb1f07a10","acronym":"","url":"https://clinicaltrials.gov/study/NCT06326463","created_at":"2024-03-23T00:36:37.002Z","updated_at":"2024-07-02T16:34:26.603Z","phase":"Phase 1","brief_title":"CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies","source_id_and_acronym":"NCT06326463","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" CD70","pipe":"","alterations":" ","tags":["CD70"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • mesna"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 07/01/2024","start_date":" 07/01/2024","primary_txt":" Primary completion: 07/01/2030","primary_completion_date":" 07/01/2030","study_txt":" Completion: 07/01/2031","study_completion_date":" 07/01/2031","last_update_posted":"2024-06-13"},{"id":"f788184e-3946-4215-8882-b92922df8fd1","acronym":"","url":"https://clinicaltrials.gov/study/NCT02436707","created_at":"2021-01-18T11:40:02.216Z","updated_at":"2024-07-02T16:34:26.702Z","phase":"Phase 2","brief_title":"Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma","source_id_and_acronym":"NCT02436707","lead_sponsor":"Canadian Cancer Trials Group","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Imbruvica (ibrutinib) • gemcitabine • Rituxan (rituximab) • cyclophosphamide • etoposide IV • Xpovio (selinexor) • dexamethasone • mesna • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 320","initiation":"Initiation: 10/27/2015","start_date":" 10/27/2015","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-06-12"},{"id":"c2c40e25-bf03-4412-bf0e-9712fe410547","acronym":"","url":"https://clinicaltrials.gov/study/NCT04947501","created_at":"2021-07-01T14:54:45.053Z","updated_at":"2024-07-02T16:34:27.282Z","phase":"Phase 1","brief_title":"A Study of N9 Chemotherapy in Children With Neuroblastoma","source_id_and_acronym":"NCT04947501","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" MYCN","pipe":" | ","alterations":" MYCN amplification","tags":["MYCN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • vincristine • topotecan • mesna • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 06/22/2021","start_date":" 06/22/2021","primary_txt":" Primary completion: 06/22/2025","primary_completion_date":" 06/22/2025","study_txt":" Completion: 06/22/2025","study_completion_date":" 06/22/2025","last_update_posted":"2024-06-11"},{"id":"fe8da34f-8155-4e53-a434-b93819c389c5","acronym":"OPTIMIZE","url":"https://clinicaltrials.gov/study/NCT06001385","created_at":"2023-08-21T14:08:42.896Z","updated_at":"2024-07-02T16:34:27.204Z","phase":"Phase 2","brief_title":"HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis","source_id_and_acronym":"NCT06001385 - OPTIMIZE","lead_sponsor":"Center for International Blood and Marrow Transplant Research","biomarkers":" HLA-DRB1 • HLA-B • HLA-DPB1 • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B • HLA-DPB1 • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • melphalan • fludarabine IV • mesna • busulfan"],"overall_status":"Recruiting","enrollment":" Enrollment 190","initiation":"Initiation: 12/08/2023","start_date":" 12/08/2023","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2024-06-11"},{"id":"92222cde-38f1-4798-9e7b-0b2b4361f314","acronym":"","url":"https://clinicaltrials.gov/study/NCT05436418","created_at":"2022-06-29T15:59:10.686Z","updated_at":"2024-07-02T16:34:38.201Z","phase":"Phase 1/2","brief_title":"The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation","source_id_and_acronym":"NCT05436418","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IGH • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["IGH • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • sirolimus • melphalan • fludarabine IV • mesna • Neupogen (filgrastim)"],"overall_status":"Recruiting","enrollment":" Enrollment 240","initiation":"Initiation: 11/18/2022","start_date":" 11/18/2022","primary_txt":" Primary completion: 06/25/2027","primary_completion_date":" 06/25/2027","study_txt":" Completion: 07/02/2027","study_completion_date":" 07/02/2027","last_update_posted":"2024-06-05"},{"id":"cd5cf9d3-98a9-4678-a914-8b4e2b5f403f","acronym":"ACCESS","url":"https://clinicaltrials.gov/study/NCT04904588","created_at":"2021-05-27T12:53:04.457Z","updated_at":"2024-07-02T16:35:01.309Z","phase":"Phase 2","brief_title":"HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide","source_id_and_acronym":"NCT04904588 - ACCESS","lead_sponsor":"Center for International Blood and Marrow Transplant Research","biomarkers":" HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-DPB1 • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-DPB1 • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • melphalan • fludarabine IV • mesna • busulfan • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 09/30/2021","start_date":" 09/30/2021","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2024-05-23"},{"id":"db508520-4ea9-4c84-8d31-9c56429ac8f4","acronym":"","url":"https://clinicaltrials.gov/study/NCT01798004","created_at":"2021-01-18T07:57:29.532Z","updated_at":"2024-07-02T16:35:15.000Z","phase":"Phase 1","brief_title":"Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma","source_id_and_acronym":"NCT01798004","lead_sponsor":"Children's Oncology Group","biomarkers":" MYCN","pipe":" | ","alterations":" MYCN amplification • MYCN expression","tags":["MYCN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification • MYCN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • topotecan • melphalan • mesna • busulfan • Neupogen (filgrastim) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 04/08/2013","start_date":" 04/08/2013","primary_txt":" Primary completion: 07/28/2015","primary_completion_date":" 07/28/2015","study_txt":"","study_completion_date":"","last_update_posted":"2024-03-13"},{"id":"365bcd51-2ab8-4615-b16d-85cc815ed781","acronym":"","url":"https://clinicaltrials.gov/study/NCT01505569","created_at":"2021-01-18T06:19:27.289Z","updated_at":"2025-02-25T14:00:01.019Z","phase":"","brief_title":"Auto Transplant for High Risk or Relapsed Solid or CNS Tumors","source_id_and_acronym":"NCT01505569","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" MYCN • CD34","pipe":" | ","alterations":" LDH elevation • MYCN expression","tags":["MYCN • CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LDH elevation • MYCN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • paclitaxel • ifosfamide • etoposide IV • melphalan • mesna • thiotepa • busulfan"],"overall_status":"Completed","enrollment":" Enrollment 44","initiation":"Initiation: 10/20/2011","start_date":" 10/20/2011","primary_txt":" Primary completion: 02/01/2024","primary_completion_date":" 02/01/2024","study_txt":" Completion: 02/01/2024","study_completion_date":" 02/01/2024","last_update_posted":"2024-02-26"},{"id":"b62639b3-3bfc-4f4f-81ac-2892933d901a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05115630","created_at":"2021-11-10T14:13:02.708Z","updated_at":"2024-07-02T16:35:19.132Z","phase":"Phase 1/2","brief_title":"Off-the-shelf NK Cells + SCT for Myeloid Malignancies","source_id_and_acronym":"NCT05115630","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • FLT3 • ABL1 • BCR • NPM1 • RUNX1 • ASXL1 • KMT2A • MECOM • NUP214 • GATA2 • DEK","pipe":" | ","alterations":" TP53 mutation • FLT3 mutation • RUNX1 mutation • ASXL1 mutation • MLL rearrangement • Chr del(5q) • FLT3 wild-type","tags":["TP53 • FLT3 • ABL1 • BCR • NPM1 • RUNX1 • ASXL1 • KMT2A • MECOM • NUP214 • GATA2 • DEK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • FLT3 mutation • RUNX1 mutation • ASXL1 mutation • MLL rearrangement • Chr del(5q) • FLT3 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • melphalan • fludarabine IV • mesna • Neupogen (filgrastim) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 04/08/2022","start_date":" 04/08/2022","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2024-02-16"},{"id":"d2d12dcf-dfdb-45f6-91d9-456c82f31467","acronym":"","url":"https://clinicaltrials.gov/study/NCT05589896","created_at":"2022-10-21T13:55:53.196Z","updated_at":"2024-07-02T16:35:19.225Z","phase":"Phase 1/2","brief_title":"A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies","source_id_and_acronym":"NCT05589896","lead_sponsor":"Ossium Health, Inc.","biomarkers":" HLA-DRB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • mesna • busulfan • Neupogen (filgrastim)"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 03/30/2024","start_date":" 03/30/2024","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2024-02-15"},{"id":"a555d72e-a833-4298-a799-b874d7c7606c","acronym":"","url":"https://clinicaltrials.gov/study/NCT00338377","created_at":"2021-01-18T01:10:12.317Z","updated_at":"2024-07-02T16:35:20.425Z","phase":"Phase 2","brief_title":"Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma","source_id_and_acronym":"NCT00338377","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" IL2","pipe":"","alterations":" ","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • mesna • Proleukin (aldesleukin) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1230","initiation":"Initiation: 02/01/2006","start_date":" 02/01/2006","primary_txt":" Primary completion: 02/28/2030","primary_completion_date":" 02/28/2030","study_txt":" Completion: 02/28/2030","study_completion_date":" 02/28/2030","last_update_posted":"2024-02-07"},{"id":"53124618-2267-481b-8fe0-bf52fc60b679","acronym":"","url":"https://clinicaltrials.gov/study/NCT00936936","created_at":"2021-01-18T03:38:02.528Z","updated_at":"2024-07-02T16:35:20.708Z","phase":"Phase 2","brief_title":"High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors","source_id_and_acronym":"NCT00936936","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • gemcitabine • docetaxel • ifosfamide • etoposide IV • melphalan • mesna"],"overall_status":"Completed","enrollment":" Enrollment 64","initiation":"Initiation: 06/02/2009","start_date":" 06/02/2009","primary_txt":" Primary completion: 01/11/2024","primary_completion_date":" 01/11/2024","study_txt":" Completion: 01/11/2024","study_completion_date":" 01/11/2024","last_update_posted":"2024-02-06"},{"id":"7b20d6d4-1189-47d1-bd64-55eb31d095f7","acronym":"HAP2HCT","url":"https://clinicaltrials.gov/study/NCT03849651","created_at":"2021-01-18T19:00:01.850Z","updated_at":"2024-07-02T16:35:22.870Z","phase":"Phase 2","brief_title":"TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies","source_id_and_acronym":"NCT03849651 - HAP2HCT","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" FLT3 • RUNX1 • KMT2A • ETV6 • WT1 • CREBBP • NUP98 • NSD1 • HOXA9 • NUP214 • CBFA2T3 • GLIS2 • KAT6A • KDM5A • DEK • AFDN • MLLT10","pipe":" | ","alterations":" FLT3-ITD mutation • WT1 mutation • MLL fusion • NUP98-NSD1 fusion","tags":["FLT3 • RUNX1 • KMT2A • ETV6 • WT1 • CREBBP • NUP98 • NSD1 • HOXA9 • NUP214 • CBFA2T3 • GLIS2 • KAT6A • KDM5A • DEK • AFDN • MLLT10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • WT1 mutation • MLL fusion • NUP98-NSD1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Blincyto (blinatumomab) • melphalan • fludarabine IV • mesna • thiotepa • Neupogen (filgrastim) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 01/31/2019","start_date":" 01/31/2019","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2024-01-19"},{"id":"7442a163-6eec-47a9-bb41-9d083af1512d","acronym":"","url":"https://clinicaltrials.gov/study/NCT01857934","created_at":"2021-01-18T08:18:15.837Z","updated_at":"2024-07-02T16:35:23.492Z","phase":"Phase 2","brief_title":"Therapy for Children With Advanced Stage Neuroblastoma","source_id_and_acronym":"NCT01857934","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" MYCN","pipe":" | ","alterations":" MYCN amplification","tags":["MYCN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • topotecan • melphalan • mesna • Proleukin (aldesleukin) • busulfan • Unituxin (dinutuximab) • Leukine (sargramostim) • Neupogen (filgrastim) • cyclophosphamide intravenous • humanised dinutuximab (Hu14.18K322A)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 153","initiation":"Initiation: 07/05/2013","start_date":" 07/05/2013","primary_txt":" Primary completion: 10/21/2021","primary_completion_date":" 10/21/2021","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-01-15"},{"id":"65bb320b-04cd-4429-8955-978641d62230","acronym":"","url":"https://clinicaltrials.gov/study/NCT04678401","created_at":"2021-01-19T20:46:09.736Z","updated_at":"2024-07-02T16:35:24.583Z","phase":"Phase 1","brief_title":"IS-free Treg HaploHCT","source_id_and_acronym":"NCT04678401","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" TP53 • HLA-DRB1","pipe":" | ","alterations":" TP53 mutation","tags":["TP53 • HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • mesna • thiotepa • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 01/12/2021","start_date":" 01/12/2021","primary_txt":" Primary completion: 10/31/2025","primary_completion_date":" 10/31/2025","study_txt":" Completion: 10/31/2027","study_completion_date":" 10/31/2027","last_update_posted":"2024-01-04"},{"id":"319e00c1-4042-4b5b-bae6-7484ffcf0d6f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02880293","created_at":"2021-01-18T14:08:25.525Z","updated_at":"2024-07-02T16:35:28.538Z","phase":"","brief_title":"Haploidentical (Half-matched) Related Donor Stem Cell Transplantation Using Killer Immunoglobulin-like Receptors in Addition to Normal Selection Factors to Determine the Best Donor","source_id_and_acronym":"NCT02880293","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" TP53 • FLT3 • ABL1 • BCR • RUNX1 • ASXL1 • CRLF2 • IKZF1","pipe":" | ","alterations":" TP53 mutation • FLT3 mutation • RUNX1 mutation • ASXL1 mutation • IKZF1 mutation • MLL mutation","tags":["TP53 • FLT3 • ABL1 • BCR • RUNX1 • ASXL1 • CRLF2 • IKZF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • FLT3 mutation • RUNX1 mutation • ASXL1 mutation • IKZF1 mutation • MLL mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • melphalan • fludarabine IV • mesna • thiotepa • Neupogen (filgrastim) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 44","initiation":"Initiation: 08/23/2016","start_date":" 08/23/2016","primary_txt":" Primary completion: 11/20/2023","primary_completion_date":" 11/20/2023","study_txt":" Completion: 11/20/2023","study_completion_date":" 11/20/2023","last_update_posted":"2023-11-21"}]